Pharmacology of Hypolipidemic Drugs

1. Introduction/Overview

Dyslipidemia represents a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), a leading cause of global morbidity and mortality. The pharmacological management of dyslipidemia, primarily through the use of hypolipidemic drugs, constitutes a cornerstone of preventive cardiology. These agents target various components of lipid metabolism to reduce circulating levels of atherogenic lipoproteins, particularly low-density lipoprotein cholesterol (LDL-C), and to modulate other lipid fractions such as triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C). The evolution of hypolipidemic therapy has been guided by extensive epidemiological and interventional trial data, demonstrating that reductions in LDL-C are linearly associated with decreased risk of major adverse cardiovascular events. This chapter provides a systematic examination of the pharmacology of agents used to treat dyslipidemia, encompassing their mechanisms, clinical applications, and safety profiles.

Learning Objectives

• Classify major hypolipidemic drug classes based on their primary mechanism of action and chemical structure.
• Explain the molecular and cellular pharmacodynamics of statins, ezetimibe, PCSK9 inhibitors, fibrates, bile acid sequestrants, and other lipid-modifying agents.
• Compare and contrast the pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, of different hypolipidemic drugs.
• Evaluate the clinical indications, therapeutic efficacy, and evidence base for each drug class in the management of primary and secondary prevention of ASCVD.
• Identify major adverse effects, drug interactions, and special population considerations for safe and effective prescribing of hypolipidemic medications.

2. Classification

Hypolipidemic drugs are categorized according to their primary mechanism of action and their predominant effects on specific lipid parameters. A functional classification is most clinically relevant.

Drug Classes and Categories

• HMG-CoA Reductase Inhibitors (Statins): Atorvastatin, simvastatin, rosuvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin.
• Cholesterol Absorption Inhibitors: Ezetimibe.
• PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors: Alirocumab, evolocumab (monoclonal antibodies); inclisiran (small interfering RNA).
• Fibric Acid Derivatives (Fibrates): Fenofibrate, gemfibrozil, bezafibrate.
• Bile Acid Sequestrants (Resins): Cholestyramine, colestipol, colesevelam.
• Nicotinic Acid (Niacin): Immediate-release, extended-release formulations.
• Omega-3 Fatty Acid Preparations: Icosapent ethyl, prescription omega-3-acid ethyl esters.
• Microsomal Triglyceride Transfer Protein (MTP) Inhibitor: Lomitapide (restricted use).
• Angiopoietin-like 3 (ANGPTL3) Inhibitor: Evinacumab (monoclonal antibody).

Chemical Classification

Chemical diversity exists within and between classes. Statins are structurally classified as type I (fermentation-derived, lovastatin, simvastatin) and type II (fully synthetic, atorvastatin, rosuvastatin, fluvastatin). Fibrates are derivatives of fibric acid, with fenofibrate being a prodrug. Bile acid sequestrants are non-absorbable polymeric resins. The chemical heterogeneity underpins differences in pharmacokinetics, particularly metabolism.

3. Mechanism of Action

The mechanisms by which hypolipidemic drugs lower plasma lipid concentrations are diverse, targeting synthesis, absorption, catabolism, and clearance of lipoproteins.

HMG-CoA Reductase Inhibitors (Statins)

Statins competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the de novo cholesterol biosynthesis pathway within hepatocytes. This inhibition reduces intracellular cholesterol synthesis, leading to a compensatory upregulation of hepatic LDL receptor (LDLR) expression via sterol regulatory element-binding protein-2 (SREBP-2) pathways. Increased LDLR density on hepatocyte surfaces enhances the clearance of LDL and LDL precursors (intermediate-density lipoproteins, IDL) from the circulation, resulting in a pronounced reduction in plasma LDL-C levels. Beyond lipid-lowering, statins exhibit pleiotropic effects, including improvement of endothelial function, stabilization of atherosclerotic plaques, anti-inflammatory actions, and anti-thrombotic properties, which may contribute to their clinical benefits.

Cholesterol Absorption Inhibitors

Ezetimibe acts locally at the brush border of the small intestine by selectively inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein. This protein is responsible for the uptake of dietary and biliary cholesterol into enterocytes. By blocking this transporter, ezetimibe reduces the intestinal absorption of cholesterol by approximately 50%, leading to a decrease in the delivery of cholesterol to the liver. This depletion of hepatic cholesterol stores subsequently triggers an increase in LDLR expression, enhancing clearance of LDL-C from plasma. Its mechanism is complementary to that of statins.

PCSK9 Inhibitors

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that binds to hepatic LDL receptors, promoting their lysosomal degradation and thus reducing the number of LDLRs available to clear circulating LDL-C. Monoclonal antibody inhibitors (alirocumab, evolocumab) bind circulating PCSK9 with high affinity, preventing its interaction with the LDLR. This inhibition preserves LDLR recycling and increases the number of functional LDLRs on hepatocytes, markedly enhancing LDL-C clearance. Inclisiran, a small interfering RNA (siRNA) therapeutic, acts at a pre-translational level by inducing RNA interference, leading to degradation of PCSK9 mRNA and sustained reduction of PCSK9 protein synthesis.

Fibric Acid Derivatives (Fibrates)

Fibrates are agonists of the peroxisome proliferator-activated receptor-alpha (PPAR-α), a nuclear transcription factor. Activation of PPAR-α alters the expression of numerous genes involved in lipid metabolism. Key effects include: stimulation of lipoprotein lipase (LPL) expression, enhancing the catabolism of triglyceride-rich lipoproteins (chylomicrons and VLDL); reduction of apolipoprotein C-III (apo C-III) production, an inhibitor of LPL; and increased synthesis of apolipoprotein A-I and A-II, leading to elevated HDL-C levels. The primary lipid effect is a substantial reduction in plasma triglycerides (30-50%) with a modest increase in HDL-C (5-20%). Their effect on LDL-C is variable and often modest.

Bile Acid Sequestrants

These non-absorbable anion-exchange resins bind bile acids in the intestinal lumen, forming an insoluble complex that is excreted in feces. This interruption of the enterohepatic circulation of bile acids depletes the hepatic bile acid pool. The liver compensates by converting more cholesterol into bile acids, utilizing hepatic cholesterol stores. This depletion upregulates LDLR expression via the SREBP-2 pathway, increasing clearance of LDL-C from plasma. They may also modestly increase HDL-C and have no effect on, or may slightly increase, triglycerides.

Nicotinic Acid (Niacin)

The precise mechanism for niacin’s lipid-modifying effects is not fully elucidated but is mediated through its action on the G protein-coupled receptor GPR109A (HM74A) in adipocytes and immune cells. This inhibits hormone-sensitive lipase, reducing the mobilization of free fatty acids (FFA) from peripheral adipose tissue to the liver. Reduced hepatic FFA flux decreases the substrate available for triglyceride and VLDL synthesis. Niacin also directly inhibits hepatic diacylglycerol acyltransferase 2 (DGAT2), a key enzyme in triglyceride synthesis. The net effects are reductions in VLDL and LDL production, a significant increase in HDL-C (by reducing the hepatic clearance of apolipoprotein A-I), and a reduction in lipoprotein(a) [Lp(a)].

Omega-3 Fatty Acid Preparations

The mechanisms of prescription omega-3 formulations are complex. Icosapent ethyl, the ethyl ester of eicosapentaenoic acid (EPA), reduces hepatic synthesis and secretion of VLDL triglycerides. Proposed mechanisms include: increased β-oxidation of fatty acids in the liver and peroxisomes; reduced esterification of triglycerides; and inhibition of diacylglycerol acyltransferase. It may also have beneficial non-lipid effects, including anti-inflammatory, antioxidant, and improved endothelial function. Mixed EPA/docosahexaenoic acid (DHA) preparations work through similar pathways but DHA may increase LDL-C in some individuals.

4. Pharmacokinetics

Pharmacokinetic properties significantly influence dosing regimens, drug interactions, and use in special populations.

Absorption, Distribution, Metabolism, Excretion

Statins

Absorption varies (30-98%), with peak plasma concentration (C_max) typically reached within 1-4 hours. Most statins (simvastatin, lovastatin, atorvastatin) are administered as inactive lactone prodrugs hydrolyzed to active β-hydroxyacid forms. They are extensively bound to plasma proteins (>90%). Distribution to the liver is facilitated by organic anion-transporting polypeptide (OATP) 1B1 transporters. Metabolism occurs primarily via the hepatic cytochrome P450 system: simvastatin, lovastatin, and atorvastatin are metabolized by CYP3A4; fluvastatin by CYP2C9; rosuvastatin minimally by CYP2C9; and pravastatin and pitavastatin undergo minimal CYP metabolism. Excretion is predominantly biliary/fecal, with renal excretion playing a minor role except for pravastatin and rosuvastatin. Elimination half-lives (t_1/2) range from 1-3 hours (simvastatin, pravastatin) to 14-19 hours (atorvastatin, rosuvastatin), influencing dosing frequency.

Ezetimibe

Ezetimibe is absorbed and extensively conjugated in the intestine to its active glucuronide metabolite (ezetimibe-glucuronide). The systemic concentration of the parent drug is low. Both the parent and metabolite are highly protein-bound (>90%). They undergo enterohepatic recirculation, prolonging their action at the intestinal site. Metabolism is primarily via glucuronidation (UGT1A1, 1A3). Excretion is predominantly fecal (≈78%) with minor renal elimination. The t_1/2 is approximately 22 hours.

PCSK9 Monoclonal Antibodies

Alirocumab and evolocumab are administered subcutaneously. Absorption is slow, with C_max reached in 3-7 days. They distribute primarily within the vascular and interstitial spaces. Being large proteins, they are metabolized via proteolytic catabolism throughout the body, not by hepatic CYP enzymes. Elimination occurs via intracellular degradation following fluid-phase and receptor-mediated endocytosis, with a long terminal t_1/2 of 11-20 days, allowing for dosing every 2 or 4 weeks.

Fibrates

Fenofibrate is a prodrug hydrolyzed to fenofibric acid. Gemfibrozil is active. Absorption is good, but food can enhance fenofibrate absorption. They are highly protein-bound (>95%). Metabolism involves glucuronidation (gemfibrozil) and CYP4A11/2C8/2C9 (fenofibric acid). Excretion is primarily renal as glucuronide conjugates. The t_1/2 varies: gemfibrozil 1.5 hours, fenofibric acid 20 hours.

Bile Acid Sequestrants

These polymers are not absorbed from the gastrointestinal tract. They act locally in the intestine and are excreted unchanged in feces. Consequently, they have no systemic pharmacokinetics, which minimizes systemic drug interactions but can bind other orally administered drugs in the gut.

Half-life and Dosing Considerations

Dosing schedules are directly linked to elimination half-life. Statins with longer half-lives (atorvastatin, rosuvastatin, pitavastatin) can be administered at any time of day, while those with shorter half-lives (simvastatin, lovastatin, pravastatin) are typically dosed in the evening to coincide with peak endogenous cholesterol synthesis. The long half-lives of PCSK9 monoclonal antibodies permit infrequent subcutaneous administration. Bile acid sequestrants are typically dosed multiple times daily with meals to maximize bile acid binding.

5. Therapeutic Uses/Clinical Applications

The selection of hypolipidemic therapy is guided by the specific lipid abnormality, the magnitude of ASCVD risk, patient comorbidities, and tolerability.

Approved Indications

• Statins: First-line therapy for primary and secondary prevention of ASCVD. Indicated for lowering elevated LDL-C, total cholesterol, and apo B, and to reduce cardiovascular events. Also used in dyslipidemias associated with diabetes and familial hypercholesterolemia.
• Ezetimibe: Adjunctive therapy to statins for further LDL-C reduction when statin monotherapy is insufficient or statin-intolerant. Also indicated for homozygous sitosterolemia.
• PCSK9 Inhibitors: Adjunctive therapy to diet and maximally tolerated statin therapy in patients with clinical ASCVD or heterozygous familial hypercholesterolemia (HeFH) requiring additional LDL-C lowering. Evolocumab is also indicated for homozygous familial hypercholesterolemia (HoFH).
• Fibrates: First-line for severe hypertriglyceridemia (TG ≥ 500 mg/dL) to prevent pancreatitis. Also used in mixed dyslipidemia (elevated TG with low HDL-C), particularly when statins are contraindicated or insufficient for triglyceride control.
• Bile Acid Sequestrants: Adjunctive therapy for LDL-C reduction. May be considered in patients who cannot tolerate statins, in young adults, or in pregnancy (Category B).
• Icosapent Ethyl: Adjunctive therapy to reduce cardiovascular risk in patients with established ASCVD or diabetes with other risk factors, who have elevated triglycerides (≥150 mg/dL) despite statin therapy.
• Niacin: Use has declined due to marginal net clinical benefit in outcome trials and significant side effects. Historically used for mixed dyslipidemia and to raise HDL-C.

Off-label Uses

Statins are sometimes used in conditions with inflammatory components (e.g., certain autoimmune diseases) for potential pleiotropic benefits, though this remains an area of investigation. Omega-3 fatty acids are widely used for various conditions, but only specific prescription formulations have cardiovascular indications.

6. Adverse Effects

The tolerability and safety profiles of hypolipidemic drugs are critical determinants of adherence and therapeutic success.

Common Side Effects

• Statins: Myalgia (muscle aches without creatine kinase elevation) is most common (1-10%). Other effects include headache, dyspepsia, diarrhea, and insomnia.
• Ezetimibe: Generally well-tolerated. Side effects may include diarrhea, abdominal pain, fatigue, and upper respiratory tract infections.
• PCSK9 Inhibitors: Injection site reactions (erythema, pain, bruising) are the most frequent adverse events. Nasopharyngitis and influenza-like symptoms may occur.
• Fibrates: Gastrointestinal disturbances (dyspepsia, abdominal pain), rash, and dizziness. Fenofibrate is associated with a lower risk of myopathy with concomitant statin use compared to gemfibrozil.
• Bile Acid Sequestrants: Gastrointestinal effects are predominant, including constipation, bloating, flatulence, and dyspepsia. May interfere with fat-soluble vitamin absorption (A, D, E, K) with long-term use.
• Niacin: Nearly universal cutaneous flushing and pruritus (mediated by prostaglandin D2). Other effects include gastrointestinal upset, hyperglycemia, and hyperuricemia.

Serious/Rare Adverse Reactions

• Statins:
  • Myopathy/Rhabdomyolysis: A spectrum from myalgia to life-threatening rhabdomyolysis with acute kidney injury. Risk is dose-dependent and increased with drug interactions (especially with CYP3A4 inhibitors like clarithromycin, azole antifungals, cyclosporine, gemfibrozil).
  • Hepatotoxicity: Asymptomatic, reversible elevations in serum transaminases (ALT, AST) occur in 1-3% of patients. Frank hepatitis is rare.
  • New-Onset Diabetes Mellitus: A small increased risk (≈0.1% per year of treatment) of developing diabetes, particularly with higher-intensity statin therapy in predisposed individuals.
  • Neurocognitive Effects: Reports of memory loss or confusion, though evidence from large trials is inconsistent.
• Fibrates: Increased risk of myositis and rhabdomyolysis, especially when combined with statins (notably gemfibrozil). Cholelithiasis due to increased cholesterol secretion into bile. Reversible elevation in serum creatinine.
• Niacin: Hepatotoxicity (more common with sustained-release formulations), including fulminant hepatic failure. May precipitate gout attacks. Can worsen glycemic control in diabetes.
• Omega-3 Fatty Acids: Atrial fibrillation and bleeding events have been observed in some outcome trials, though the risk-benefit profile for icosapent ethyl remains favorable in indicated populations.

Black Box Warnings

Statins carry a black box warning for the risk of myopathy/rhabdomyolysis. They are also contraindicated in pregnancy (Category X) due to potential fetal harm. Lomitapide, used for HoFH, has a black box warning for hepatotoxicity and requires intensive monitoring.

7. Drug Interactions

Interactions can alter efficacy or increase toxicity, necessitating careful review of concomitant medications.

Major Drug-Drug Interactions

• Statins (CYP3A4 substrates – simvastatin, lovastatin, atorvastatin):
  • Potent CYP3A4 Inhibitors: Azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin), HIV protease inhibitors, cyclosporine, grapefruit juice (large quantities). These dramatically increase statin exposure and myopathy risk. Co-administration is often contraindicated.
  • Gemfibrozil: Inhibits statin glucuronidation and OATP1B1 transport, significantly increasing statin plasma levels. Fenofibrate is a safer combination if needed.
• Gemfibrozil: Interacts with numerous drugs via CYP2C8/2C9 inhibition and glucuronidation inhibition. Increases levels of repaglinide, pioglitazone, and statins.
• Bile Acid Sequestrants: Bind many oral drugs in the gut (e.g., warfarin, digoxin, thyroxine, thiazide diuretics, statins, ezetimibe). Administration of other drugs should be spaced 1 hour before or 4-6 hours after the resin.
• Ezetimibe: Minimal CYP-based interactions. Bile acid sequestrants reduce its absorption; dosing should be separated.
• PCSK9 Inhibitors: No clinically significant pharmacokinetic drug interactions identified due to their catabolic pathway.

Contraindications

• Absolute: Active liver disease or unexplained persistent transaminase elevations (for statins, niacin, fibrates). Pregnancy and lactation (statins, Category X). Hypersensitivity to any component.
• Relative/Precautions: Concomitant use of potent CYP inhibitors with specific statins. Renal impairment (dose adjustment required for many statins, fibrates). History of myopathy. Gallbladder disease (fibrates). Peptic ulcer disease (niacin). Bleeding disorders (omega-3 fatty acids).

8. Special Considerations

Patient-specific factors necessitate tailored therapeutic approaches.

Use in Pregnancy and Lactation

Statins are contraindicated (Category X) due to theoretical risks of fetal malformations from cholesterol synthesis inhibition. Bile acid sequestrants (Category B) are considered the drugs of choice for severe hypercholesterolemia in pregnancy as they are not systemically absorbed. Ezetimibe, fibrates, niacin, and PCSK9 inhibitors should generally be avoided due to lack of safety data. Most hypolipidemic drugs are not recommended during breastfeeding.

Pediatric and Geriatric Considerations

In pediatric patients with familial hypercholesterolemia, statins (e.g., atorvastatin, rosuvastatin) are approved for use in children as young as 8-10 years. Dosing is weight-based and initiated at the lowest dose. In geriatric patients, age-related declines in renal and hepatic function may increase the risk of adverse effects. Lower starting doses of renally excreted statins (pravastatin, rosuvastatin) and fibrates are often recommended. Polypharmacy increases the risk of drug interactions.

Renal and Hepatic Impairment

Renal Impairment: Statins excreted renally (pravastatin, rosuvastatin) may require dose reduction in severe chronic kidney disease (CKD). Atorvastatin and fluvastatin require less adjustment. Fibrates are contraindicated in severe renal impairment due to increased myotoxicity risk; fenofibrate requires dose adjustment in moderate CKD. Ezetimibe can be used without dose adjustment.

Hepatic Impairment: Statins, fibrates, and niacin are contraindicated in active liver disease or decompensated cirrhosis due to risk of hepatotoxicity. They should be used with caution in patients with chronic stable liver disease, with regular monitoring of liver enzymes. Bile acid sequestrants and ezetimibe may be safer options as they have minimal hepatic metabolism, though resins can worsen pruritus in cholestasis.

9. Summary/Key Points

• Hypolipidemic drugs are essential for reducing ASCVD risk by modifying plasma lipoprotein concentrations, with LDL-C reduction being the primary therapeutic target.
• Statins remain first-line therapy due to robust evidence for cardiovascular event reduction, acting via HMG-CoA reductase inhibition to upregulate hepatic LDL receptor activity.
• Ezetimibe and PCSK9 inhibitors provide complementary mechanisms for additional LDL-C lowering, targeting intestinal cholesterol absorption and LDL receptor degradation, respectively.
• Fibrates are first-line for severe hypertriglyceridemia to prevent pancreatitis, acting primarily as PPAR-α agonists to enhance triglyceride-rich lipoprotein clearance.
• Bile acid sequestrants offer a non-systemic option for LDL-C reduction but are limited by gastrointestinal side effects and drug-binding interactions.
• Icosapent ethyl is an evidence-based adjunct to statins to reduce residual cardiovascular risk in patients with elevated triglycerides.
• Major safety concerns include statin-associated muscle symptoms and myopathy, hepatotoxicity (with several classes), and specific drug interactions, particularly involving CYP450 enzymes.
• Therapeutic selection must be individualized based on the lipid profile, absolute cardiovascular risk, comorbidities, concomitant medications, and patient preferences.

Clinical Pearls

• Before initiating therapy, exclude secondary causes of dyslipidemia (e.g., hypothyroidism, nephrotic syndrome, obstructive liver disease).
• Monitor for therapeutic response and safety: check a fasting lipid panel 4-12 weeks after initiation or dose change, and assess liver enzymes and creatine kinase as clinically indicated.
• For statin-intolerant patients, consider strategies such as dose reduction, alternate-day dosing, or switching to a different statin before abandoning the class. Ezetimibe or a PCSK9 inhibitor can be used as monotherapy if statins are completely contraindicated.
• When combining a statin with a fibrate, fenofibrate is preferred over gemfibrozil due to a lower risk of myotoxicity, and the lowest effective doses of both should be used.
• Lifestyle modifications, including a heart-healthy diet, regular physical activity, and weight management, are foundational and should accompany all pharmacologic therapy.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.